New Directions in Chronic Lymphocytic Leukemia Care: A Review of 2019 Treatment Guideline Updates

Published: Monday, Jul 08, 2019
blood cellsDIn December 2018, pivotal trial data were presented at the American Society of Hematology Annual Meeting that demonstrated promising results for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). In particular, new courses of CLL care in several patient populations emerged from the findings of 3 trials: the Alliance North American Intergroup Study A041202 (ALLIANCE),1 the E1912 trial of the ECOG-ACRIN Cancer Research Group (ECOG E1912),2 and iLLUMINATE.3

The impact of these studies is reinforced by the updates to the 2019 National Comprehensive Cancer Network (NCCN) guidelines for the treatment of CLL. The updated guidelines reflect the increased consideration now given to frailty, significant comorbidities, age, del(17p)/TP53 mutation status, and immunoglobulin heavy-chain variable (IGHV) mutation status in patients with CLL (Table).4 This article reviews the guideline updates.


First-Line Options Combined for Frail Patients With Significant Comorbidity, Patients Older Than 65 Years, and Younger Patients With Significant Comorbidities Without del(17p)/TP53 Mutation

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication